| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562179924P | 2015-05-22 | 2015-05-22 |
| Publication Number | Publication Date |
|---|---|
| SG10202007661XAtrue SG10202007661XA (en) | 2020-09-29 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202007661XASG10202007661XA (en) | 2015-05-22 | 2016-05-23 | Therapeutic uses of l-4-chlorokynurenine |
| Country | Link |
|---|---|
| US (3) | US20180140568A1 (en) |
| EP (2) | EP4108239A1 (en) |
| JP (3) | JP2018521007A (en) |
| KR (2) | KR20240068766A (en) |
| CN (1) | CN107949379A (en) |
| AU (3) | AU2016268153B2 (en) |
| BR (1) | BR112017024908A2 (en) |
| CA (1) | CA3024783A1 (en) |
| DK (1) | DK3297619T3 (en) |
| EA (1) | EA201792571A1 (en) |
| ES (1) | ES2925274T3 (en) |
| IL (3) | IL296380A (en) |
| MX (1) | MX395492B (en) |
| PL (1) | PL3297619T3 (en) |
| PT (1) | PT3297619T (en) |
| SG (1) | SG10202007661XA (en) |
| SI (1) | SI3297619T1 (en) |
| WO (1) | WO2016191351A1 (en) |
| ZA (1) | ZA201707874B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6436913B2 (en) | 2013-01-22 | 2018-12-12 | ヴィスタゲン セラピューティクス、インコーポレイテッド | Dosage form and therapeutic use of L-4-chlorokynurenine |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CN114007600A (en)* | 2019-04-09 | 2022-02-01 | 维斯塔津治疗公司 | Genetic variation associated with therapeutic response to neurological disorders |
| IL299301A (en)* | 2020-06-24 | 2023-02-01 | Biohaven Therapeutics Ltd | Compositions and methods for treating obsessive-compulsive disorder |
| WO2022221423A1 (en)* | 2021-04-13 | 2022-10-20 | Vistagen Therapeutics, Inc. | Treatment of autoimmune anti-nmda-receptor encephalitis |
| CN115677519A (en)* | 2021-07-22 | 2023-02-03 | 立科时代(武汉)生物科技有限公司 | L-4-bromo-kynurenine and application thereof in preparation of drugs for treating depression |
| WO2024011105A1 (en)* | 2022-07-05 | 2024-01-11 | Mahana Therapeutics, Inc. | Methods and systems for treating tinnitus using digital therapeutics |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5484814A (en) | 1991-02-28 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| EP1061924A1 (en)* | 1998-03-09 | 2000-12-27 | Trustees Of Tufts College | Treatment of compulsive behaviours in man and animals |
| TW518218B (en)* | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| WO2002045710A1 (en)* | 2000-12-07 | 2002-06-13 | Neuromolecular Inc. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| US20060063802A1 (en)* | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| NZ571761A (en)* | 2006-04-12 | 2010-07-30 | Probiodrug Ag | 5-phenylimidazoles |
| US8058243B2 (en)* | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
| AU2008323877A1 (en)* | 2007-11-06 | 2009-05-14 | Emory University | Methods of identifying safe NMDA receptor antagonists |
| TW201026667A (en)* | 2008-09-30 | 2010-07-16 | Merz Pharma Gmbh & Co Kgaa | Glycine b antagonists |
| US20140057988A1 (en)* | 2012-08-23 | 2014-02-27 | Stuart WEG | Anxiolytic composition, formulation and method of use |
| JP6436913B2 (en)* | 2013-01-22 | 2018-12-12 | ヴィスタゲン セラピューティクス、インコーポレイテッド | Dosage form and therapeutic use of L-4-chlorokynurenine |
| JP2016513718A (en) | 2013-03-14 | 2016-05-16 | ヴィスタゲン セラピューティクス、インコーポレイテッド | Synthesis of chiral kynurenine compounds and intermediates |
| EP2970097B1 (en) | 2013-03-14 | 2018-10-31 | Vistagen Therapeutics, Inc. | Methods for the synthesis of chiral kynurenine compounds |
| KR20220102662A (en)* | 2014-05-06 | 2022-07-20 | 노쓰웨스턴유니버시티 | Combinations of nmdar modulating compounds |
| Publication number | Publication date |
|---|---|
| HK1257800A1 (en) | 2019-11-01 |
| PT3297619T (en) | 2022-08-05 |
| EP3297619A4 (en) | 2019-01-02 |
| AU2021209279A1 (en) | 2021-08-19 |
| US20190321317A1 (en) | 2019-10-24 |
| JP2022064908A (en) | 2022-04-26 |
| AU2021209279B2 (en) | 2023-09-14 |
| ES2925274T3 (en) | 2022-10-14 |
| WO2016191351A1 (en) | 2016-12-01 |
| IL255770A (en) | 2018-01-31 |
| AU2016268153B2 (en) | 2021-08-12 |
| JP2024050575A (en) | 2024-04-10 |
| KR20180015158A (en) | 2018-02-12 |
| EP3297619B1 (en) | 2022-07-06 |
| DK3297619T3 (en) | 2022-08-15 |
| AU2016268153A1 (en) | 2017-12-14 |
| IL255770B (en) | 2021-09-30 |
| IL285882A (en) | 2021-09-30 |
| MX395492B (en) | 2025-03-25 |
| ZA201707874B (en) | 2020-01-29 |
| JP2018521007A (en) | 2018-08-02 |
| MX2017014456A (en) | 2018-03-16 |
| KR20240068766A (en) | 2024-05-17 |
| BR112017024908A2 (en) | 2018-07-31 |
| CN107949379A (en) | 2018-04-20 |
| EP4108239A1 (en) | 2022-12-28 |
| SI3297619T1 (en) | 2023-02-28 |
| AU2023282234A1 (en) | 2024-01-18 |
| US20180140568A1 (en) | 2018-05-24 |
| US20240122887A1 (en) | 2024-04-18 |
| CA3024783A1 (en) | 2016-12-01 |
| EA201792571A1 (en) | 2018-06-29 |
| IL296380A (en) | 2022-11-01 |
| PL3297619T3 (en) | 2023-02-13 |
| EP3297619A1 (en) | 2018-03-28 |
| Publication | Publication Date | Title |
|---|---|---|
| IL250685A0 (en) | Cytotoxicity-inducing therapeutic agent | |
| HUE051354T2 (en) | Therapeutic | |
| GB201513540D0 (en) | Therapeutic agents | |
| IL258997B (en) | Honey-cannabinoid therapeutic composition | |
| GB201509893D0 (en) | Therapeutic agents | |
| IL285882A (en) | Therapeutic uses of l-4-chlorokynurenine | |
| GB201517263D0 (en) | Therapeutic agents | |
| GB201512365D0 (en) | Novel therapy | |
| ZA201802256B (en) | Compounds and therapeutic uses thereof | |
| GB201410216D0 (en) | Therapeutic | |
| GB201509885D0 (en) | Therapeutic agents | |
| GB201502412D0 (en) | Therapeutic use | |
| IL255498A (en) | Treatment of pruritus | |
| GB201509888D0 (en) | Therapeutic agents | |
| GB201416788D0 (en) | Therapeutic applications for pyocins | |
| GB201510637D0 (en) | Therapeutic | |
| GB201516068D0 (en) | Novel therapy | |
| GB201513299D0 (en) | Therapeutic agents | |
| GB201505382D0 (en) | Novel therapy | |
| GB201506786D0 (en) | Therapeutic use | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201514729D0 (en) | Treatment of haemorrhoids | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201512635D0 (en) | Uses of therapeutic compounds | |
| GB201518805D0 (en) | Therapy |